Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Type 2 Diabetes, Persistent Pain
Phase NA
Enrollment 319
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to examine the efficacy of cognitive bias modification for interpretation (CBM-I) in people with Type 2 Diabetes and persistent pain. The main question\[s\] it aims to answer is whether interpretation bias training away from pain improves pain outcomes. Participants in the CBM-I group will complete 4 online training sessions approximately half an hour each. Each session will present participants with ambiguous scenarios which may be pain-related, however the final word of the sentence will resolve the scenario as benign (thus training participants to make benign interpretations). A measure of interpretation bias will be administered following the fourth training session, and pain severity and interference will be measured at baseline, post-training, two week follow up, and three month follow up. The study hypothesises that participants in the CBM-I group will demonstrate a greater reduction in the co-primary outcomes of pain severity and pain interference over time compared to those in the placebo control.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Behavioral: Cognitive Bias Modification for Interpretation — Cognitive Bias Modification involves administering the Ambiguous Scenarios paradigm. This is a series of ambiguous scenarios which could be resolved to be associated with pain. The task consists of 30 unique scenarios and an associated comprehension question (pertaining to the pain-relatedness of the scenario), which are presented in a random order to participants. Each scenario presents an ambiguous sentence, ending with a word fragment which the participant must complete. The statement remains ambiguous until the completion of the word fragment, which resolves the statement as either pain-related or benign. For example, the statement "You are bush walking. Suddenly, you trip over and fall onto your knees. Your knees feel all wet, and you look down to see..." can be followed by "le\_v\_s \[leaves\]" for a benign resolution, or "bl\_\_d \[blood\]" for a pain-related resolution. In the intervention group, all 30 scenarios will be followed with the benign word fragment.
  • Behavioral: Placebo — The Ambiguous Scenarios paradigm described previously will be used for the placebo intervention. The same 30 scenarios will be presented to participants, however 50% (15) trials will be followed by the benign word fragment, ad 50% (15) trials will be followed by the pain-related word fragment.

Primary Outcomes

  • Pain severity (Baseline, post intervention (day 14), Pre intervention session 2 (day 4), pre intervention session 3 (day 7) [primary timepoint], two week follow up post intervention (day 28) [primary timepoint], three month post intervention follow up (3 months))
  • Pain interference (Baseline, post intervention (day 14), Pre intervention session 2 (day 4), pre intervention session 3 (day 7) [primary timepoint], two week follow up post intervention (day 28) [primary timepoint], three month post intervention follow up (3 months))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-15
Completion: 2025-10-15
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 319 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Sydney
Principal Investigators:
  • Louise Sharpe (PRINCIPAL_INVESTIGATOR) - University of Sydney
Contact Information
Study Contact:
Tessa Rooney
+61449610131
tessa.rooney@sydney.edu.au
Tessa Rooney
+61449610131
tessa.rooney@sydney.edu.au
University of Sydney
Interventions
  • Behavioral: Cognitive Bias Modification for Interpretation — Cognitive Bias Modification involves administering the Ambiguous Scenarios paradigm. This is a series of ambiguous scenarios which could be resolved to be associated with pain. The task consists of 30 unique scenarios and an associated comprehension question (pertaining to the pain-relatedness of the scenario), which are presented in a random order to participants. Each scenario presents an ambiguous sentence, ending with a word fragment which the participant must complete. The statement remains ambiguous until the completion of the word fragment, which resolves the statement as either pain-related or benign. For example, the statement "You are bush walking. Suddenly, you trip over and fall onto your knees. Your knees feel all wet, and you look down to see..." can be followed by "le\_v\_s \[leaves\]" for a benign resolution, or "bl\_\_d \[blood\]" for a pain-related resolution. In the intervention group, all 30 scenarios will be followed with the benign word fragment.
  • Behavioral: Placebo — The Ambiguous Scenarios paradigm described previously will be used for the placebo intervention. The same 30 scenarios will be presented to participants, however 50% (15) trials will be followed by the benign word fragment, ad 50% (15) trials will be followed by the pain-related word fragment.
Study Locations (1 sites)
University of Sydney, Camperdown, New South Wales 2006 Australia
Eligibility Criteria
Inclusion Criteria: * Over 18 years of age * Have a diagnosis of Type 2 diabetes. * Have persistent pain (pain present on more days than not, for 3 months or longer). * Score ≥ 3 on average pain severity on the Brief Pain Inventory (BPI). * Fluent in English * Have access to internet and ability to use a computer over a three month period. Exclusion Criteria: * Under 18 years of age * No diagnosis of Type 2 diabetes * No persistent pain * Not fluent in English * No access to internet nor ability to use a computer.
Conditions Type 2 Diabetes Mellitus (T2DM), Type 2 ...
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

The investigators are hoping to determine whether tailoring the diet of someone with type 2 diabetes to their ethnic group while following American Diabetes Association guidelines can make a significant difference in their blood sugar controls. Participants will be required to wear a Continuous Glucose Monitor (CGM) for 1-month so that the investigators can compare blood sugar levels when participants are eating their routine diet vs. the culturally tailored diabetes diet.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: NOURISH Diet — NOURISH meals will be prepared by NOURISH chefs for seven days. Both South Asian and Filipino meal plans will be prepared, vegetarian, vegan and non-vegetarian options available for all. Participants will pick-up NOURISH meals at a Stanford facility and consume three meals (breakfast, lunch, and dinner) and two snacks over one week. There will be no caloric restriction, the calories in each meal will be informed by the average intake for the participants gender and BMI.
  • Other: Self-Selected Diet (Control) — The participants will eat their routine meals without any involvement of the investigators. Participants will be required to wear the CGM during this time and keep a detailed food log through Tastermonial.

Primary Outcomes

  • Change in Positive Area Under the Curve (pAUC) for Blood Glucose (During Week 2, Week 3)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-08-31
Completion: 2027-04
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Stanford University
Collaborators: Tastermonial Inc
Principal Investigators:
  • Minal Moharir, MD (PRINCIPAL_INVESTIGATOR) - Stanford University
Contact Information
Study Contact:
Arati Nagarkar
619-241-6884
arati.nagarkar@stanford.edu
Stanford University
Mehek Parghi
510-512-0586
mparghi@stanford.edu
Stanford University
Interventions
  • Other: NOURISH Diet — NOURISH meals will be prepared by NOURISH chefs for seven days. Both South Asian and Filipino meal plans will be prepared, vegetarian, vegan and non-vegetarian options available for all. Participants will pick-up NOURISH meals at a Stanford facility and consume three meals (breakfast, lunch, and dinner) and two snacks over one week. There will be no caloric restriction, the calories in each meal will be informed by the average intake for the participants gender and BMI.
  • Other: Self-Selected Diet (Control) — The participants will eat their routine meals without any involvement of the investigators. Participants will be required to wear the CGM during this time and keep a detailed food log through Tastermonial.
Study Locations (1 sites)
Stanford University, Stanford, California 94305 United States
Eligibility Criteria
Inclusion Criteria: * Self-identification as Asian Indian or Filipino * Diagnosed with T2DM * Pick up and consume personally tailored cultural food and meal options for 1 week * Willing to wear a CGM for 30 days Exclusion Criteria: * Currently taking insulin * Known severe allergic reactions and/or food intolerances that would interfere with the ability to eat * Those who, in the opinion of the investigators, cannot reliably complete the study protocol.
Conditions Obesity Type 2 Diabetes Mellitus, Obesit...
Phase NA
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

This pilot study will evaluate the feasibility, acceptability, and perceived usefulness of the SWITCH mobile nutrition behavioral intervention among adults receiving GLP-1 receptor agonist therapy for obesity and/or type 2 diabetes. Participants will complete baseline assessments, receive a 6-week app-based nutrition intervention consisting of daily dietary self-monitoring and weekly learning modules, and complete follow-up assessments and a structured interview.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Behavioral: SWITCH Diets - Mobile Nutrition Behavioral Intervention — SWITCH Diets is a mobile health nutrition intervention adapted for adults receiving GLP-1 therapy. Participants track food intake daily in the app and receive tailored goals for fiber, potassium, magnesium, and protein, based on baseline characteristics. The app provides visual feedback on progress toward nutrient goals and weekly learning modules with diet-related education, audio/video content, recipes, and quizzes.

Primary Outcomes

  • Intervention acceptability, usefulness and ease of use (End of 6-week intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04-06
Completion: 2027-04-01
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of South Carolina
Contact Information
Study Contact:
Shiba Bailey
8035765688
SB25@email.sc.edu
Carolina Delgado-Diaz, PhD
803-777-3932
delgadoc@mailbox.sc.edu
University South Carolina
Shiba Bailey, PhD
University South Carolina
Interventions
  • Behavioral: SWITCH Diets - Mobile Nutrition Behavioral Intervention — SWITCH Diets is a mobile health nutrition intervention adapted for adults receiving GLP-1 therapy. Participants track food intake daily in the app and receive tailored goals for fiber, potassium, magnesium, and protein, based on baseline characteristics. The app provides visual feedback on progress toward nutrient goals and weekly learning modules with diet-related education, audio/video content, recipes, and quizzes.
Study Locations (1 sites)
University South Carolina, Columbia, South Carolina 29208 United States
Eligibility Criteria
Inclusion Criteria: * • Age between 18 and 65 years. * BMI between 30 - 49.9 kg/m2 and/or diagnosed with type 2 diabetes. * Currently prescribed and using GLP-1 receptor therapy for at least 4 weeks. * Own a smartphone (Android or iOS) with an active data plan to support app-based intervention delivery. * Residing anywhere in the United States. * Must be willing and able to reduce caloric intake. * Be free of major health or psychiatric diseases, drug, or alcohol dependency. * Willing to sign informed consent. Exclusion Criteria: * • Presence of type 1 diabetes mellitus * Severe complications, including but not limited to proliferative retinopathy, severe peripheral neuropathy, nephropathy requiring dialysis, active foot ulcers, or recent hospitalization for diabetic ketoacidosis or hyperosmolar hyperglycemic state within the past 6 months. * Current or recent (within 6 months) participation in another structured weight loss program or clinical trial that may interfere with study outcomes. * Pregnancy, breastfeeding, or plans to become pregnant during the study period. * Current use of another investigational weight loss device or medication. * Diagnosed eating disorders (e.g., anorexia nervosa, bulimia nervosa, binge eating disorder) or other psychiatric conditions that may affect adherence to behavioral interventions, as determined by study staff. * Severe cardiovascular, hepatic, renal, or pulmonary disease that would limit participation in moderate physical activity or dietary modification. * Active cancer treatment (chemotherapy, radiation, or surgery) within the past 12 months. * Substance use disorder or alcohol dependency within the past 12 months. * Cognitive impairment or any medical or mental condition that would interfere with the ability to understand or comply with study procedures. * Lack of reliable internet or smartphone access, or unwillingness to use a mobile app for tracking and communication.
Conditions Diabetes Mellitus, Type 2
Phase PHASE2
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

The study is a randomized control trial involving 100 participants (formerly incarcerated Black men with poorly controlled diabetes) to examine the effect of a tailored nurse case manager on glycemic control and other clinical outcomes, self-care behaviors, and quality of life at 6 months post-randomization.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Behavioral: MANAGe-DM - novel nurse case management — Participants assigned to MANAGe-DM will receive the standard diabetes education mailing in addition to a novel nurse case management intervention. Each month of the study period, the NCM will conduct two phone call intervention sessions with individual participants.
  • Behavioral: Monthly Educational Mailing — All participants in the study will receive diabetes education mailers. This includes monthly mailings of diabetes education, based off the American Diabetes Association guidelines for Diabetes Education. Topics covered will include diabetes basics, monitoring and medications, healthy eating and exercise, overview of common comorbidities, basics of foot care, and strategies for overcoming common pitfalls.

Primary Outcomes

  • Hemoglobin A1C (6 months post-randomization)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-02-20
Completion: 2027-12-01
Eligibility
Age: 18 Years and older
Sex: MALE
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medical College of Wisconsin
Principal Investigators:
  • Laura Hawks, MD (PRINCIPAL_INVESTIGATOR) - Medical College of Wisconsin
Contact Information
Study Contact:
Laura Hawks, MD
414-955-8020
lhawks@mcw.edu
Laura Hawks, MD
4149558020
lhawks@mcw.edu
Center for Advancing Population Science, Medical College of Wisconsin
Interventions
  • Behavioral: MANAGe-DM - novel nurse case management — Participants assigned to MANAGe-DM will receive the standard diabetes education mailing in addition to a novel nurse case management intervention. Each month of the study period, the NCM will conduct two phone call intervention sessions with individual participants.
  • Behavioral: Monthly Educational Mailing — All participants in the study will receive diabetes education mailers. This includes monthly mailings of diabetes education, based off the American Diabetes Association guidelines for Diabetes Education. Topics covered will include diabetes basics, monitoring and medications, healthy eating and exercise, overview of common comorbidities, basics of foot care, and strategies for overcoming common pitfalls.
Study Locations (1 sites)
Center for Advancing Population Science, Medical College of Wisconsin, Milwaukee, Wisconsin 53226 United States
Eligibility Criteria
Inclusion Criteria: * age ≥18 years * identify as Black or African American * identify as male * formerly incarcerated in a state or federal prison system or county jail * clinical diagnosis of type 2 diabetes with HbA1c ≥8% at the screening visit * able to communicate in English. Exclusion Criteria: * mental confusion on screening interview suggesting significant dementia * current participation in other diabetes clinical trials * active psychosis or acute mental disorder * life expectancy \<12 months * awaiting arraignment, trial, sentencing in the criminal legal system * on active surveillance by the criminal legal system, meaning on house arrest or subject to electronic monitoring
Conditions Prediabetes, Type 2 Diabetes, Obesity &A...
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

The objective of this study is to investigate the impact of hypocaloric time-restricted eating (TRE) at different day times (early versus late TRE) on glucose metabolism and other cardiometabolic parameters in individuals with overweight and with normal, or impaired glucose metabolism (prediabetes and type 2 diabetes). In addition, the study aims to elucidate the molecular mechanisms underlying these effects.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Early Time-Restricted Eating — Participants will restrict their eating window (8 hours eating and 16 hours fasting per day) and caloric intake moderately. During the early TRE intervention, participants will primarily consume their meals in the morning. The precise eating window will be defined based on the individual chronotype of the participants. Additionally, participants will be required to reduce their daily caloric consumption by 25%. They will replace one daily meal with a calorie-reduced product to facilitate caloric restriction.
  • Behavioral: Late Time-Restricted Eating — Participants will restrict their eating window (8 hours eating and 16 hours fasting per day) and caloric intake moderately. During the late TRE intervention, participants will primarily consume their meals in the evening. The precise eating window will be defined based on the individual chronotype of the participants. Additionally, participants will be required to reduce their daily caloric consumption by 25%. They will replace one daily meal with a calorie-reduced product to facilitate caloric restriction.

Primary Outcomes

  • Mean 24-hour glucose (5 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-01
Completion: 2028-02-28
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: true
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: German Institute of Human Nutrition
Collaborators: Technische Universität Dresden, University of Surrey, University of Geneva, Switzerland, Technische Universität München, Germany, German Center for Diabetes Research, University of Rovira i Virgili, Spain
Contact Information
Study Contact:
Olga Ramich, Prof. Dr.
+49 33200 882749
olga.ramich@dife.de
Bettina Schuppelius, M.Sc.
+49 33200 882692
bettina.schuppelius@dife.de
Olga Ramich, Prof. Dr.
+49 33200 882749
olga.ramich@dife.de
German Institute of Human Nutrition Potsdam-Rehbruecke
Interventions
  • Behavioral: Early Time-Restricted Eating — Participants will restrict their eating window (8 hours eating and 16 hours fasting per day) and caloric intake moderately. During the early TRE intervention, participants will primarily consume their meals in the morning. The precise eating window will be defined based on the individual chronotype of the participants. Additionally, participants will be required to reduce their daily caloric consumption by 25%. They will replace one daily meal with a calorie-reduced product to facilitate caloric restriction.
  • Behavioral: Late Time-Restricted Eating — Participants will restrict their eating window (8 hours eating and 16 hours fasting per day) and caloric intake moderately. During the late TRE intervention, participants will primarily consume their meals in the evening. The precise eating window will be defined based on the individual chronotype of the participants. Additionally, participants will be required to reduce their daily caloric consumption by 25%. They will replace one daily meal with a calorie-reduced product to facilitate caloric restriction.
Study Locations (1 sites)
German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, 14558 Germany
Eligibility Criteria
Inclusion Criteria: * Overweight or obesity (BMI 25-40 kg/m²) * Healthy glucose metabolism (fasting glucose \<100 mg/dl and glucose after 2 hours OGTT \<140 mg/dl) * OR impaired glucose metabolism (fasting glucose 100-125 mg/dl and/or glucose after 2 hours OGTT 140-199 mg/dl and/or HbA1c 5.7-6.4%) * OR type 2 diabetes (according to existing medical diagnosis or fasting glucose \>126 mg/dl and/or glucose after 2 hours OGTT \>200 mg/dl and/or HbA1c ≥6.5%) * Daily eating window ≥12 hours Exclusion Criteria: * Weight changes \> 5% within past 3 months * Shift work * Traveling across more than one time zone within one month prior to the study * Pregnancy and breastfeeding * Eating disorders, food intolerance/allergy to ingredients in the diet product, vegan diet, practicing time-restricted eating * Severe chronic illnesses or other conditions that are incompatible with the planned intervention and examination program (e.g. type 1 diabetes, recent cardiovascular event, malabsorption, cancer in the last two years, etc.) * Treatment with insulin, sulfonylureas, and GLP-1 receptor agonists, steroid use (oral, cutaneous, or parenteral), regular intake of melatonin, anticoagulation treatment that cannot be paused * Extreme early and extreme late chronotypes
Conditions Diabetes Mellitus
Phase Not Applicable
Enrollment 145
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this prospective, multicenter, observational study is to evaluate the real-world effectiveness and safety of oral and subcutaneous semaglutide in adults with type 2 diabetes mellitus in Argentina. The main objective is to assess changes in glycated hemoglobin (HbA1c) from baseline to 3, 6, and 12 months after treatment initiation. Secondary objectives include evaluating changes in body weight, waist circumference, hand-grip strength, treatment satisfaction, medication adherence, treatment route switching, treatment discontinuation, and adverse events. Participants will receive semaglutide as prescribed by their treating physician as part of routine clinical care. Follow-up assessments will be performed at 3, 6, and 12 months to collect clinical, laboratory, safety, treatment satisfaction, and adherence data. Treatment satisfaction will be assessed using the Diabetes Treatment Satisfaction Questionnaire (DTSQ), and adherence will be assessed using the Simplified Medication Adherence Questionnaire (SMAQ).

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Drug: semaglutide — Participants will receive semaglutide as part of their usual medical care for type 2 diabetes mellitus. The intervention of interest includes both oral and subcutaneous formulations of semaglutide, prescribed and dosed at the discretion of the treating physician according to routine clinical practice.

Primary Outcomes

  • Change in glycated hemoglobin (HbA1c) levels from baseline to 3, 6, and 12 months of follow-up. (Baseline, 3 months, 6 months, and 12 months.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-08-04
Completion: 2028-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 145 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hospital Italiano de Buenos Aires
Principal Investigators:
  • María Natalia Nachón, MD (PRINCIPAL_INVESTIGATOR) - Hospital General de Agudos Dr Enrique Tornú
  • Iván A Huespe, MD (STUDY_DIRECTOR) - Hospital Italiano de Buenos Aires
  • Matías Mirofsky, MD (STUDY_CHAIR) - Hospital Leónidas Lucero, Bahía Blanca
Contact Information
Study Contact:
Martín L Gil Folgar, MD
1520497361
martin.gilfolgar@hospitalitaliano.org.ar
Natalia Nachón, MD
155876-3407
dra.nachon@gmail.com
Martín L Gil Folgar, MD
1520497361
martin.gilfolgar@hospitalitaliano.org.ar
Hospital Italiano de Buenos Aires
Interventions
  • Drug: semaglutide — Participants will receive semaglutide as part of their usual medical care for type 2 diabetes mellitus. The intervention of interest includes both oral and subcutaneous formulations of semaglutide, prescribed and dosed at the discretion of the treating physician according to routine clinical practice.
Study Locations (2 sites)
Hospital Italiano de Buenos Aires, Buenos Aires, Buenos Aires 1199 Argentina
Hospital General de Agudos Dr Enrique Tornú, Buenos Aires, Buenos Aires 1427 Argentina
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years. * Clinical diagnosis of type 2 diabetes mellitus. * Baseline glycated hemoglobin (HbA1c) \>7% and ≤12%. * Initiating treatment with semaglutide (oral or subcutaneous) prescribed by the treating physician according to clinical judgment. Exclusion Criteria: * Pregnancy or lactation at the time of enrollment. * History of severe hypersensitivity or adverse reactions to glucagon-like peptide-1 (GLP-1) receptor agonists. * Contraindications to semaglutide as listed in the product label (e.g., severe gastrointestinal disease, certain endocrine tumors). * Any other serious medical condition that, in the investigator's opinion, may interfere with study participation or data interpretation.
Conditions Type 2 Diabetes Mellitus (T2DM)
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

Type 2 diabetes in increasing common in young adults. Utilizing a mixed-methods, community-based approach, this study offers continuous glucose monitors (CGMs) to young adults with type 2 diabetes for 30 days, and collects both quantitative and qualitative data to understand barriers and facilitators of CGM use, participants' changes in awareness of glucose patterns while using the CGM, and preferences for a CGM-based self-management intervention.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Continuous glucose monitor — Participants will wear a continuous glucose monitoring sensor for 30 days. They will also wear a FitBit wrist watch to be able to track their physical activity and they will complete weekly surveys to report diabetes self-management behaviors. After the 30 days, they will participate in a qualitative interview to respond to questions about their experiences.

Primary Outcomes

  • Qualitative data regarding CGM use (Immediately after the intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-02
Completion: 2026-07-30
Eligibility
Age: 18 Years – 45 Years
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: San Diego State University
Collaborators: Scripps Health
Principal Investigators:
  • Jessica L McCurley, PhD MPH (PRINCIPAL_INVESTIGATOR) - San Diego State University
Contact Information
Study Contact:
Jessica L McCurley, PhD, MPH
619-594-2132
jlmccurley@sdsu.edu
Samantha Bagsic, PhD
858-554-5708
Bagsic.Samantha@scrippshealth.org
Scripps Health
Interventions
  • Device: Continuous glucose monitor — Participants will wear a continuous glucose monitoring sensor for 30 days. They will also wear a FitBit wrist watch to be able to track their physical activity and they will complete weekly surveys to report diabetes self-management behaviors. After the 30 days, they will participate in a qualitative interview to respond to questions about their experiences.
Study Locations (1 sites)
Scripps Health, San Diego, California 92121 United States
Eligibility Criteria
Inclusion Criteria: * adult 18-45 years of age * diagnosis of type 2 diabetes in the last 5 years, as evidenced in the electronic medical record * no prior use or experience with wearable CGMs * possession of a smart phone that is compatible with Dexcom CGM sensors (nearly all smartphones are compatible) and willing to download and utilize the Dexcom CGM app * fluency in English or Spanish Exclusion Criteria: * severe mental illness (e.g., psychosis, suicidal ideation); * pregnancy or \<6 months postpartum
Conditions Type 2 Diabetes
Phase PHASE1
Enrollment 56
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

This is 2-part study. The primary objective of Part 1 is to evaluate safety and tolerability of single subcutaneous (SC) doses of PATAS in healthy subjects. The secondary objective of this study is to determine the pharmacokinetics (PK) of single SC doses of PATAS in healthy subjects. The primary objectives of Part 2 are to evaluate the safety and tolerability of 4 weekly SC doses of PATAS in subjects with T2D; and to determine the PK and pharmacodynamics (PD) of 4 weekly SC doses of PATAS in subjects with T2D. Secondary objectives of Part 2 include evaluation of the potential effect of multiple SC doses of PATAS on markers of glycemic control, as measured by glucose levels, insulin levels, and other metabolomic biomarkers and characterization of of adverse event (AE) profiles of the various dose levels of PATAS.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: PATAS Trifluoroacetate — A drug targeting the interaction between the ALMS1 protein and alpha-PKC
  • Drug: Placebo — Excipient only formulation, without active compound

Primary Outcomes

  • Phase 1B: Safety (29 days)
  • OGTT (Baseline, Day 28)
  • Cmax (Pre-dose, Day 1, Day 2, Day 8, Day 15, Day 22, Day 23)
  • Tmax (Pre-dose, Day 1, Day 2, Day 8, Day 15, Day 22, Day 23)
  • AUClast (Pre-dose, Day 1, Day 2, Day 8, Day 15, Day 22, Day 23)
  • AUCinf (Pre-dose, Day 1, Day 2, Day 8, Day 15, Day 22, Day 23)
  • T1/2 (Pre-dose, Day 1, Day 2, Day 8, Day 15, Day 22, Day 23)
  • CL/F (Pre-dose, Day 1, Day 2, Day 8, Day 15, Day 22, Day 23)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-01-27
Completion: 2027-05-30
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 56 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: AdipoPharma LLC
Principal Investigators:
  • Vincent Marion, Ph.D. (STUDY_CHAIR) - AdipoPharma LLC
Contact Information
Study Contact:
Tarek Hiwot, M.D.
44 7391 537 158
tarek.hiwot@adipopharma.us
Michael J Fare
203-671-4351
michael.fare@adipopharma.us
Samantha Zuniga
480-470-4000
szuniga@azclinicaltrials.com
Arizona Clinical Trials
Interventions
  • Drug: PATAS Trifluoroacetate — A drug targeting the interaction between the ALMS1 protein and alpha-PKC
  • Drug: Placebo — Excipient only formulation, without active compound
Study Locations (3 sites)
Arizona Clinical Trials, Chandler, Arizona 85225 United States
Clinical Pharmacology of Miami, Miami, Florida 33072 United States
Progressive Medical Research, Port Orange, Florida 32127 United States
Eligibility Criteria
Inclusion Criteria: * Part 1: Single Ascending Dose Inclusion criteria 1. Healthy male and female subjects, 18 to 55 years of age, inclusive, at the time of signing the Informed Consent Form (ICF); 2. Willing and able to give written informed consent for participation in the study prior to the initiation of any Screening or study-specific procedures; 3. Body mass index (BMI) within the range of 20.0 to 35.0 kg/m2, inclusive, at Screening; 4. In generally good health, as judged by the Investigator, based upon medical/surgical history and the results of physical examination, vital signs, clinical laboratory assessments, and 12-lead electrocardiogram (ECG) at Screening and at Check-In (Day -1); 5. Female subjects must have a negative serum pregnancy test result at the Screening Visit and a negative urine pregnancy test at Check-In (Day -1) (prior to the first dose of study drug) and must not be pregnant, lactating, or planning a pregnancy from the Screening Visit to 90 days after the last dose of study drug; 6. Negative test result for severe acute respiratory syndrome coronavirus 2 at Check-In (Day -1); and 7. Willing to comply with all study procedures and requirements throughout the duration of the study. Exclusion Criteria: <!-- --> 1. Clinically significant history of asthma, eczema, or any other allergic condition or previous severe hypersensitivity; Note: Non-active hay fever is not exclusionary. 2. Liver function tests (alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], alkaline phosphatase \[ALP\], total bilirubin) outside the following upper limits of normal (ULNs) at Screening or at Check-In (Day -1): a. For ALT and AST, measurements \> ULN; b. For ALP, measurements \>ULN; or c. For total bilirubin, measurements \> ULN. 3. Estimated glomerular filtration rate \</= 90 mL/min/1.73 m2 based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation at Screening or at Check-In (Day -1); 4. Thyroid-stimulating hormone (TSH) outside of reference range (e.g., TSH \<1 × lower limit of normal \[LLN\] or TSH \>1 × ULN) at Screening; Note: Abnormal TSH results will reflex to a free thyroxine (T4) test. 5. History of unexplained syncope, cardiac arrest, unexplained cardiac arrythmias or torsades de pointes, or structural heart disease; 6. Personal or family history of long QT syndrome; 7. Clinically significant history of any disease or disorder (i.e., gastrointestinal, cardiovascular, respiratory, renal, hepatic, neurological, dermatological, psychiatric, or metabolic) deemed to be exclusionary, as judged by the Investigator; 8. Abnormal pulse rate or blood pressure (BP) measurements at Screening, defined as: a. Pulse rate \<40 bpm or \>100 bpm; b. Systolic BP \< 90 mmHg or \>140 mmHg; or c. Diastolic BP \< 50 mmHg or \> 90 mmHg. 9. Clinically significant ECG abnormalities at Screening or at Check-In (Day -1), defined as prolongation of the average QTcF interval \> 450 ms for males and \>470 ms for females, or other clinically significant ECG abnormalities per Investigator discretion; 10. Positive for hepatitis B surface antigen, HIV antibody, or hepatitis C virus antibody at Screening; 11. Receipt of any investigational product within 30 days prior to first study drug administration (90 days for investigational biologic agents) or 5 half-lives prior to first study drug administration, whichever is greater, or participation in \>3 clinical studies within 12 months; 22. Known or suspected hypersensitivity to PATAS or any components of the formulation used (sodium hydroxide or mannitol); Part 2: Multiple Ascending Dose Inclusion Criteria 1. Male and female subjects, 18 to 65 years of age, inclusive, at the time of signing the ICF; 2. Willing and able to give written informed consent for participation in the study prior to the initiation of any Screening or study-specific procedures; 3. A diagnosis of T2D \>6 months before Screening 4. Subjects should be on a stable dose of 1. an oral monotherapy (permitted monotherapies include metformin and dipeptidyl peptidase 4 inhibitors) for at least 90 days before Screening 2. or a dual therapy (including metformin and dipeptidyl peptidase 4 inhibitors) for at least 6 months before Screening 3. or managing the condition through diet and exercise for at least 90 days before Screening; 5. Glycated hemoglobin 7 % and \<10.5% at Screening; 6. BMI within the range of 25.0 to 40.0 kg/m2, inclusive, at Screening; 7. In generally good health, as judged by the Investigator, based upon medical/surgical history and the results of physical examination, vital signs, clinical laboratory assessments, and 12-lead ECG at Screening and at the pre-dose Check-In (Day -1); 8. Female subjects must have a negative serum pregnancy test result at the Screening Visit and a negative urine pregnancy test at the pre-dose Check-In (Day -1) (priorto the first dose of study drug) and must not be pregnant, lactating, or planning a pregnancy from the Screening Visit to 90 days after the last dose of study drug; 9. Female subjects of childbearing potential (i.e., ovulating, premenopausal, and not permanently surgically sterile) with male partners and all male subjects with female partners of childbearing potential will be included if they are either sexually inactive (complete abstinence from heterosexual activity if in line with the subject's preferred and usual lifestyle) and agree to continue complete abstinence for 90 days after the last administration of study drug, or, if sexually active, agree to use an effective contraceptive regimen during their participation in the study and for 90 days after the last administration of study drug. Effective contraceptive methods are defined as those with 90% or greater efficacy and include the following: * For male subjects enrolled in the study: Condoms with spermicide; or Surgical sterilization (vasectomy) of the subject at least 6 months before Screening. * For female subjects enrolled in the study: Intrauterine device for at least 90 days before Screening; Hormonal contraception (combination oral contraceptives, progestin-only oral contraceptives that inhibit ovulation, hormonal implants, progestin only injections, rings, or patches) for at least 90 days before Screening; or Bilateral tubal ligation for at least 90 days before Screening. Note: Sexual abstinence is considered an effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. Abstinence is only acceptable if in line with the subject's preferred and usual lifestyle. Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea methods are not acceptable methods of contraception. 10. Female subjects of nonchildbearing potential will be included if they meet the following definition of nonchildbearing potential: are either surgically sterile (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy at least 90 days before the Screening Visit) or postmenopausal, defined as spontaneous amenorrhea for at least 1 year, with FSH in the postmenopausal range at Screening, based on the central laboratory's ranges; and 11. Willing to comply with all study procedures and requirements throughout the duration of the study. Part 2 Multiple Ascending Dose Inclusion Criteria 1. Poorly controlled diabetes which will interfere with participation in the trial in the opinion of the Investigator, e.g., brittle diabetes, extreme fluctuation of glucoses; 2. History of diabetic ketoacidosis or hyperosmolar coma in the 6 months prior to Screening; 3. History of level 3 hypoglycemia in the 6 months prior to Screening or a history of hypoglycemia unawareness; 4. History or current evidence of type 1 diabetes or any other form of diabetes (e.g., latent autoimmune diabetes in adults, m
Conditions Diabetes Mellitus, Type 2
Phase Not Applicable
Enrollment 240
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

A. Four groups of patients with type 2 diabetes mellitus with high or very high cardiovascular risk or heart failure with preserved ejection fraction (HFpEF) will be studied before and at 6 and 12 months of treatment: * 60 patients treated with a combination of GLP1 analogue and SGLT2 inhibitor ± metformin * 60 patients treated with GLP-1 agonist as a second step after metformin * 60 patients treated with SGLT2 inhibitor as a second step after metformin * 60 patients treated with a combination of insulin and other antidiabetic agents (metformin - DPP4 inhibitors) Individuals will be equal distributed as far as age, gender and body mass index concerned. In addition, patients suffered from kidney disease and retinopathy are excluded.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Comparison of Global Longitudinal Strain (GLS) difference among treatment groups. (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2017-11-03
Completion: 2027-06-30
Eligibility
Age: 45 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 240 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Athens
Principal Investigators:
  • Ignatios Ikonomidis, Prof (PRINCIPAL_INVESTIGATOR) - 2nd Department of Cardiology, National and Kapodistrian University of Athens
  • Aimilianos N. Kalogeris, MD (PRINCIPAL_INVESTIGATOR) - 2nd Department of Cardiology, University of Athens
  • John A. Thymis, MD (PRINCIPAL_INVESTIGATOR) - 2nd Department of Cardiology,University of Athens
Contact Information
Study Contact:
Ignatios Ikonomidis, Prof.
00306944805732
ignoik@gmail.com
Aimilianos N. Kalogeris, MD
00306949630300
kalogeris.cardio@gmail.com
Ignatios Ikonomidis, MD
"Attikon" University General Hospital
Interventions
N/A
Study Locations (1 sites)
"Attikon" University General Hospital, Athens, Attica 12462 Greece
Eligibility Criteria
Inclusion Criteria: * Subject has type 2 diabetes mellitus * Subject has high or very high cardiovascular risk * Subject has heart failure with preserved ejection fraction Exclusion Criteria: * Subject has type 1 diabetes mellitus * Subject has kidney disease * Subject has retinopathy
Conditions Diabete Type 2
Phase NA
Enrollment 5
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

English, Hindi and Gujarati

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Magnetic Compression Anastomosis — This is an Investigator Initiated trial, prospective, single-center, single-arm observational study in patients with Type II Diabetes Mellitus (T2DM). A total of 5 patients with T2DM will be recruited in the study. Following the administration of general anesthesia, surgeon will introduce the ring component of the magnetic compression anastomosis system through an enterotomy. Laparoscopic techniques are employed to maneuver the bowel, aligning the proximal and distal magnets for effective magnetic coupling and observing the ring pair mating via intraoperative imaging (fluoroscopy or plain x-ray).

Primary Outcomes

  • Placement success rate - ≥ 90% alignment of magnets Passage of magnets without surgical re-intervention Safety (Changes in glycosylated hemoglobin A1c (HbA1c) levels will be observed from baseline, 3 months, 6 months, 9 months and at 12 months following the index procedure.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-22
Completion: 2026-09-30
Eligibility
Age: 25 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 5 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: iIDEAS Group Holdings Limited
Contact Information
Study Contact:
Purvi A Chavda, MD
8905818034
purvi@curexbio.com
Purvi A Chavda, MD
08905818034
purvi@curexbio.com
AB Plus Speciality Hospital
Interventions
  • Device: Magnetic Compression Anastomosis — This is an Investigator Initiated trial, prospective, single-center, single-arm observational study in patients with Type II Diabetes Mellitus (T2DM). A total of 5 patients with T2DM will be recruited in the study. Following the administration of general anesthesia, surgeon will introduce the ring component of the magnetic compression anastomosis system through an enterotomy. Laparoscopic techniques are employed to maneuver the bowel, aligning the proximal and distal magnets for effective magnetic coupling and observing the ring pair mating via intraoperative imaging (fluoroscopy or plain x-ray).
Study Locations (1 sites)
AB Plus Speciality Hospital, Ahmedabad, Gujarat 380054 India
Eligibility Criteria
Inclusion Criteria: * Subjects will be included in the study if they meet the following criteria: 1. Participant is willing and able to give informed consent for participation in the study. 2. Male or Female, aged ≥ 25 years to ≤ 65 years. 3. BMI greater than or equal to 25 and less than 50 4. Clinical diagnosis of T2DM by plasma glucose criteria, either the fasting plasma glucose (FPG) value or the 2-h plasma glucose (2-h PG) value during a 75-g oral glucose tolerance test (OGTT), or A1C criteria 5. Glycated Hemoglobin greater than or equal to 7.5% and less than 10.5% in at least one laboratory analysis conducted within the past 3 months, typically associated with a recommendation by patient's primary care physician and/or endocrinologist for intensification of treatment beyond oral medications 6. Currently taking oral combination therapy for T2DM 7. At least 12 months of experience with Diabetes Self-Management and Support Exclusion Criteria: * 1\. Pregnancy or breastfeeding mothers, or individuals planning to become pregnant in next 9-12 months 2. Vulnerable individuals (mentally disabled, physically disabled, prisoner, etc.) 3. Current enrolment in another research study or previous participation within 30 days of enrolment 4. Current history of injected Glucagon Like Peptide 1 (GLP1) 5. American Society of Anesthesiologists (ASA) physical classification level of 4 or greater 6. Hypoglycemia unawareness or a history of severe hypoglycemia (more than 1 severe hypoglycemic event, as defined by need for third-party-assistance, in the last year) 7. Evidence of type 1 diabetes or of pancreatic exhaustion, as indicated by a C peptide fasting level less than 1 or, for type 1 diabetes, based on measurable levels of serum anti-GAD-65 autoantibodies or, at investigator's discretion, based on measurable levels of other T1D-associated autoantibodies 8. History of highly unusual or challenging gastrointestinal tract anatomy ascertained through earlier endoscopic examination or other diagnostic imaging 9. History of (or known to be at prohibitive risk for) any of the following diseases of the small bowel or closely related conditions: Crohn's disease or other inflammatory bowel disease, celiac disease, resection for cancer, or intra-abdominal adhesive disease including intussusception, perforated appendix and Meckel's diverticulum 10. History of small bowel surgery such as small bowel resection 11. Active H. pylori infection (prospective participants with active H. pylori may continue with the screening process if they are treated via medication and re-testing verifies the condition has resolved.) 12. History of chronic or acute pancreatitis 13. Known active hepatitis or active liver disease 14. Symptomatic gallstones or kidney stones or acute cholecystitis Subjects will be deemed ineligible to participate if they fulfill any of the following criteria: 1. Pregnancy or breastfeeding mothers, or individuals planning to become pregnant in next 9-12 months 2. Vulnerable individuals (mentally disabled, physically disabled, prisoner, etc.) 3. Current enrolment in another research study or previous participation within 30 days of enrolment 4. Current history of injected Glucagon Like Peptide 1 (GLP1) 5. American Society of Anesthesiologists (ASA) physical classification level of 4 or greater 6. Hypoglycemia unawareness or a history of severe hypoglycemia (more than 1 severe hypoglycemic event, as defined by need for third-party-assistance, in the last year) 7. Evidence of type 1 diabetes or of pancreatic exhaustion, as indicated by a C peptide fasting level less than 1 or, for type 1 diabetes, based on measurable levels of serum anti-GAD-65 autoantibodies or, at investigator's discretion, based on measurable levels of other T1D-associated autoantibodies 8. History of highly unusual or challenging gastrointestinal tract anatomy ascertained through earlier endoscopic examination or other diagnostic imaging 9. History of (or known to be at prohibitive risk for) any of the following diseases of the small bowel or closely related conditions: Crohn's disease or other inflammatory bowel disease, celiac disease, resection for cancer, or intra-abdominal adhesive disease including intussusception, perforated appendix and Meckel's diverticulum 10. History of small bowel surgery such as small bowel resection 11. Active H. pylori infection (prospective participants with active H. pylori may continue with the screening process if they are treated via medication and re-testing verifies the condition has resolved.) 12. History of chronic or acute pancreatitis 13. Known active hepatitis or active liver disease 14. Symptomatic gallstones or kidney stones or acute cholecystitis 15. History of coagulopathy, upper gastro-intestinal bleeding conditions such as ulcers, gastric varices, strictures, congenital or acquired intestinal telangiectasia 16. Use of anticoagulation therapy (such as warfarin) which cannot be discontinued for 7 days before and 14 days after the procedure 17. Use of P2Y12 inhibitors (clopidogrel, pasugrel, ticagrelor) which cannot be discontinued for 14 days before and 14 days after the procedure (use of low-dose aspirin allowable) 18. History of serious complications of T2DM including coronary artery disease, hypertension, peripheral vascular disease, diabetic retinopathy, and/or diabetes-related soft tissue infection 19. Taking corticosteroids or drugs known to affect GI motility (e.g. Metoclopramide) 20. Receiving weight loss medications such as Meridia, Xenical, or over-the-counter weight loss medications 21. Persistent anemia, defined as Hgb\<10 g dL-1 22. Estimated Glomerular Filtration Rate (eGFR) or Modified of Diet in Renal Disease (MDRD) \<30 ml/min/1.73m2 23. Active systemic infection 24. Currently on anticoagulation therapy other than a low-dose aspirin regimen 25. Chemotherapeutic cancer treatment within past 9 months, history of abdominal radiation, or active malignancy within the past 5 years 26. Active illicit substance abuse or alcoholism 27. Known sensitivity to possible medications used before, during, or after the Connect procedure, including but not limited to the following: sedative agents, general anesthetics, topical anesthetics, and opioid analgesics 28. Any other serological markers likely to be associated with poor outcomes
Conditions Type 2 Diabetes, Cardiovascular Risk
Phase PHASE3
Enrollment 1778
Locations 330 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

This study is being conducted to find out how well zenagamtide works and how safe it is compared to insulin glargine in participants with type 2 diabetes who are at higher risk of heart and blood vessel problems and are already taking 1 to 3 diabetes medications. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get zenagamtide, (the treatment being tested) or insulin glargine (a comparator) and which treatment participants get is decided by chance.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Zenagamtide — Zenagamtide will be administered subcutaneously using PDS290 pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm (administration to the same body part throughout the study).
  • Drug: Insulin glargine U-100 — Insulin glargine U-100 will be administered subcutaneously using SoloSTAR pen-injector to one of the body parts: thigh, abdomen or upper arm (rotation of the injection site within body parts).

Primary Outcomes

  • Non-inferiority of zenagamtide versus insulin glargine: change in haemoglobin A1c (HbA1c) (From baseline (week 0) to week 52)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-08-24
Completion: 2028-09-20
Eligibility
Age: 45 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1778 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Novo Nordisk A/S
Contact Information
Study Contact:
Novo Nordisk
(+1) 866-867-7178
clinicaltrials@novonordisk.com
Interventions
  • Drug: Zenagamtide — Zenagamtide will be administered subcutaneously using PDS290 pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm (administration to the same body part throughout the study).
  • Drug: Insulin glargine U-100 — Insulin glargine U-100 will be administered subcutaneously using SoloSTAR pen-injector to one of the body parts: thigh, abdomen or upper arm (rotation of the injection site within body parts).
Study Locations (330 sites)
Univ of Alabama Birmingham, Birmingham, Alabama 35294 United States
Eastern Shore Rsrch Inst, LLC, Fairhope, Alabama 36532 United States
Chambliss Clinical Trials, LLC, Montgomery, Alabama 36106 United States
Honor Health, Scottsdale, Arizona 85258 United States
First Valley Medical Group, Lancaster, California 93534 United States
Headlands Research CTR Lincoln, Lincoln, California 95648 United States
Torrance Clin Res Inst, Inc., Lomita, California 90717 United States
Pacific Clinical Studies, Los Alamitos, California 90720 United States
VAGLAHS Clinical Research Center (CRC), Los Angeles, California 90073 United States
Valley Clinical Trials, Inc., Northridge, California 91325 United States
Eligibility Criteria
Inclusion Criteria: * Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study. * Male or female (sex assigned at birth, inclusive of all gender identities). * Age 45 years or above at the time of signing the informed consent. * Diagnosed with type 2 diabetes (T2D) greater than or equal to (≥) 180 days before screening. * Treatment with 1-3 marketed oral glucose-lowering medications (metformin, glinide, thiazolidinedione, sodium-glucose cotransporter-2 inhibitors (SGLT2i), α-glucosidase inhibitors (AGI), or sulfonylureas (SU) as a single agent or in combination) according to local label. Treatment with oral glucose-lowering medications must be stable (same drug(s), stable daily dose(s)) before screening. * Have HbA1c as determined by central laboratory at screening, if background glucose-lowering medications does not include a SU, or if background glucose-lowering medications includes a SU. * Increased risk of cardiovascular events as evidenced by at least one of the following (a-e): * Prior myocardial infarction (MI) * Documented coronary artery disease defined by at least one of the following: -≥ 50% stenosis of coronary artery on angiography or other imaging modality. * Ischaemia documented by stress test with any imaging modality. * Prior unstable angina with electrocardiogram (ECG) changes. * Prior coronary artery bypass graft or prior percutaneous coronary intervention. * Prior stroke (ischemic or haemorrhagic stroke). * History of chronic kidney disease based on medical records or as judged by the investigator as determined by central laboratory at screening. * Symptomatic peripheral arterial disease (PAD) defined as at least one of the following: * Intermittent claudication with an ankle-brachial index (ABI) \< 0.85 at rest. * Intermittent claudication with a ≥ 50% stenosis in a lower extremity peripheral artery documented by X-ray angiography, magnetic resonance (MR) angiography, computer tomography (CT) angiography or Doppler ultrasound. * Prior revascularisation procedure of a lower extremity peripheral artery. * Lower extremity amputation at or above ankle due to atherosclerotic disease (excluding e.g., trauma or osteomyelitis) Exclusion Criteria: * Myocardial infarction, stroke, transient ischaemic attack or hospitalisation for unstable angina pectoris within 60 days before screening. * Planned coronary, carotid or peripheral artery revascularisation. * Chronic or intermittent haemodialysis or peritoneal dialysis within 90 days before screening. Diabetes- or weight related: * Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria before screening. However, insulin treatment for gestational diabetes is allowed as well as short term insulin treatment for a maximum of 14 consecutive days. * Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment), dipeptidyl peptidase 4 (DPP-4) inhibitors or amylin analogues before screening. * Participant with diabetic retinopathy or maculopathy who received treatment with retinal photocoagulation, vitrectomy or anti-Vascular Endothelial Growth Factor (anti-VEGF) within 180 days before screening or are expected to require treatment within 180 days after screening. Diabetic retinopathy or maculopathy must be verified by an eye examination performed before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination. * Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire question. * Any episodes of diabetic ketoacidosis before screening. * Uncontrolled thyroid disease as per investigator's discretion.
Conditions Type 2 Diabetes Mellitus (T2DM), Time Re...
Phase PHASE1
Enrollment 25
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

This is a clinical trial to assess how time-restricted eating (TRE) may improve kidney health and filtration patients with type 2 diabetes and increased protein content in their urine. All participants will be participating in TRE in which they follow a consistent 8-10 hour eating window everyday.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Time Restricted Eating — Participants in the TRE group with continue to follow their physicians treatment plan for type II diabetes mellitus and consume all of their food within an 8-10 hour eating window.

Primary Outcomes

  • Urine albumin-to-creatinine ratio (uACR) (Baseline and 3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-07
Completion: 2028-02
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 25 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, San Diego
Collaborators: Salk Institute for Biological Studies
Principal Investigators:
  • Pam Taub, MD (PRINCIPAL_INVESTIGATOR) - University of California, San Diego Health
Contact Information
Study Contact:
Gavin C McLaren, BA
(858) 246-2342
preventivecvresearch@health.ucsd.edu
Marissa Dzotsi, MPH
(858) 246-2715
preventivecvresearch@health.ucsd.edu
Gavin McLaren, BA
8582462342
g2mclaren@health.ucsd.edu
Altman Clinical and Translational Research Institute
Interventions
  • Behavioral: Time Restricted Eating — Participants in the TRE group with continue to follow their physicians treatment plan for type II diabetes mellitus and consume all of their food within an 8-10 hour eating window.
Study Locations (1 sites)
Altman Clinical and Translational Research Institute, La Jolla, California 92093 United States
Eligibility Criteria
Inclusion Criteria: 1. Age: 18-75 years old 2. Participants with T2DM with A1c between 6.5 and 9.0 % and on stable doses of medications who are weight-bearing and self-ambulatory. 3. uACR ( urine albumin creatinine ratio) results ≥ 30 - 300 mg. 4. Willingness to use smartphone for research procedures (Apple iOS or Android OS) 5. Baseline eating period ≥12 hours/day and sufficient logging on the mCC app. 6. Person of childbearing potential will be given a pregnancy test on study enrollment and asked to use contraception throughout the study. 7. Post-menopausal and individuals on hormone replacement therapy will be included. 8. Estimated Glomerular Filtration Rate (EGFR) \> 45 9. If participants are on cardiovascular medications (HMG CoA reductase inhibitors (statins), other lipid-modifying drugs, anti-hypertensives) no dose adjustments will be allowed during the study period 10. Participants on stable doses (consistent dose for ≥3 months) of GLP-1 receptor agonists will be included. Exclusion Criteria: 1. Participants with Type1DM and T2DM who are taking insulin, sulfonylureas, or have an HbA1c \> 9 %. 2. Estimated Glomerular Filtration Rate (EGFR) \< 45 3. Systolic BP greater than 160 mmHg and/or Diastolic BP greater than 110 mmHg (with or without treatment/medication) 4. LDL cholesterol greater than 200 mg/dL 5. Triglycerides greater than 500 mg/dL 6. Active tobacco or illicit drug use 7. Pregnant or breastfeeding individuals. 8. Currently enrolled in a weight-loss or weight-management program, 9. Currently on a special or prescribed diet for other reasons (e.g., Celiac disease), 10. On recently prescribed medication that is meant for weight loss, or has known effect on appetite suppression ( patient on stable dose for 3 months can be enrolled ). 11. History of eating disorder(s). 12. History of surgical intervention for weight management (e) active eating disorder. 13. Chronic kidney disease with an eGFR calculated based on the Modification of Diet in Renal Disease (MDRD) equation \<50mL/min/1.73m2 14. Treatment for active inflammatory and/or rheumatologic disease and cancer. 15. A major adverse cardiovascular event within the past 6 months such as acute coronary syndrome (ACS), percutaneous coronary intervention, coronary artery bypass graft surgery, hospitalization for congestive heart failure, stroke/transient ischemic attack (TIA). 16. History of Uncontrolled arrhythmia (i.e., rate-controlled atrial fibrillation/atrial flutter are not exclusion criteria) 18. Liver cirrhosis and/or significant alterations in liver function 17. History of (a) thyroid disease requiring dose titration of thyroid replacement medication(s) within the past 3 months (i.e., hypothyroidism on a stable dose of thyroid replacement therapy is not an exclusion), Shift workers with variable (e.g., nocturnal) hours. 18. Caregivers for dependents requiring frequent nocturnal care/sleep interruptions. 19. More than one trip planned to travel to a time zone with greater than a 3-hour difference during study period. 20. History of major adverse cardiovascular events within the past 1 year (acute coronary syndrome (ACS), percutaneous coronary intervention, coronary artery bypass graft surgery, hospitalization for congestive heart failure, stroke/transient ischemic attack (TIA)). 21. History of thyroid disease requiring dose titration of thyroid replacement medication(s) within the past 3 months (i.e., hypothyroidism on a stable dose of thyroid replacement therapy is not an exclusion). 22. History of adrenal disease. 23. History of malignancy undergoing active treatment, except non-melanoma skin cancer. 24. Known history of type I diabetes. 25. History of stage 4 or 5 chronic kidney disease or requiring dialysis. 26. History of HIV/AIDS. 27. Uncontrolled psychiatric disorder (including history of hospitalization for psychiatric illness).